Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Any contraindication for treatment with allergen specific immunotherapy.

Forced expiratory volume in 1 s (FEV1) or peak expiratory flow (PEF) value \<80% of the predicted normal value.

Clinically relevant allergy symptoms due to sensitization to perennial allergens (mites, molds, epithelia) or other seasonal pollen which might interfere with the safety of the IMP.

Asthma requiring a dose \> 800 μg/day of Budesonide or an equivalent, without long-lasting beta-2 agonists or requiring a dose \> of 400 μg/day of Budesonide or an equivalent plus a long-acting-β2 agonist to reach asthma control, according to the Global Initiative for Asthma (GINA 2010)

Patients with non controlled bronchial asthma within 3 months prior to Visit 1.

Patients with asthma who have been treated with systemic steroids within 3 months prior to V1.

Patients with hospital admission due to asthma exacerbations within 1 year prior to V1.

Acute or chronic inflammatory or infectious diseases of the airways.

Chronic structural diseases of the respiratory system (for example, emphysema or bronchiectasis).

Immune system diseases, both autoimmune diseases and immunodeficiency.

Any disease involving a contraindication for the use of adrenaline (for example, hyperthyroidism).

Serious uncontrolled diseases involving a risk for the subjects participating in this study

Malignant disease with activity in the last 5 years.

Excessive consumption of alcohol, drugs or medication.

Serious psychiatric, psychological or neurological disorders.

Systemic or topical treatment with beta-blocker drugs 1 week before visit 2.

Treatment with substances interfering with the immune system 2 weeks before visit 2.

Use of tricyclic, tetracyclic and IMAO antidepressants. It will not be allowed to wash up antidepressants to enter the study because of the risks of interrupting antidepressant treatment, so patients on antidepressants therapy cannot be included in the trial.

Use of systemic corticosteroids 3 months before visit 1.

Immunization with prophylactic (bacterial or viral) vaccines within 7 days before visit 1 (prophylactic vaccines are allowed during the administration of IMP period provided they are administered at least one week after IMP administration and the next IMP administration is administered at least 14 days later).

Participation of the subject in another clinical trial 30 days before visit 2

Subjects who are going to donate stem cells, blood, organs or bone marrow in the course of the study.

Female subjects who are pregnant or nursing and women with a positive pregnancy test at visit 1 or 2.

Women of childbearing potential not using highly effective methods of birth control.

Subjects who are unable to comply with the requirements of the study or who in the opinion of the investigator should not participate in the study.

What this study is about